ADC Therapeutics and Sophia Genetics Collaborate to Identify Biomarkers in Clinical Study

ADC Therapeutics and Sophia Genetics Collaborate to Identify Biomarkers in Clinical Study

Shots:

  • The companies enter into a collaboration to identify genomic markers associated with clinical response to ADCT-402 (loncastuximab tesirine). ADC Therapeutics is currently assessing ADCT-402 in P-II study in patients with r/r DLBCL
  • Sophia Genetic will analyze cell-free DNA (cfDNA) samples extracted from blood patients participating in ADC Therapeutics’ Phase II study utilizing Sophia’s technology, detecting genomic marker with clinical response to ADCT-402 
  • ADCT-402 is an ADC consisting of humanized mAb, binding to CD19 via linker to PBD dimer toxin and is being evaluated in P-Ib (NCT03684694) & P-Ib (NCT03685344) studies in combination with ibrutinib & durvalumab for R/R DLBCL or MCL & R/R DLBCL, MCL, FL respectively

Click here to­ read full press release/ article | Ref: ADC Therapeutics| Image: ADC therapeutics